J. Bryan Iorgulescu

Dr. J. Bryan Iorgulescu


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2018 in Nature
Verified
Journal Article
Closed access
PDF file
DKDerin B. Keskin
Derin B. Keskin
AAAnnabelle J. Anandappa
Annabelle J. Anandappa
JSJing Sun
Jing Sun
ITItay Tirosh
Itay Tirosh
NMNathan D. Mathewson
Nathan D. Mathewson
DRDavid A. Reardon
David A. Reardon

15 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MTMehdi Touat
Mehdi Touat
YLYvonne Y. Li
Yvonne Y. Li
ABAdam N. Boynton
Adam N. Boynton
LSLiam Spurr
Liam Spurr
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
KLKeith L. Ligon
Keith L. Ligon

21 January 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ZHZhuting Hu
Zhuting Hu
DLDonna E. Leet
Donna E. Leet
RARosa L. Allesøe
Rosa L. Allesøe
GOGiacomo Oliveira
Giacomo Oliveira
SLShuqiang Li
Shuqiang Li
POPatrick A. Ott
Patrick A. Ott

1 March 2013 in Journal of Neurosurgery: Spine
Verified
Journal Article
Open access
PDF file
ILIlya Laufer
Ilya Laufer
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
TCTalia Chapman
Talia Chapman
ELEric Lis
Eric Lis
WSWeiji Shi
Weiji Shi
MBMark H Harvey Bilsky
Mark H Harvey Bilsky
Object: Decompression surgery followed by adjuvant radiotherapy is an effective therapy for preservation or recovery of neurological function and achieving durable local disease control in patients suffering from metastatic epidural spinal cord compression (ESCC). The authors examine the outcomes of postoperative image-guided intensity-modulated radiation therapy delivered as single-fraction or hypofractionated stereotactic radiosurgery (SRS) for achieving long-term local tumor control. Methods: A retrospective chart review identified 186 patients with ESCC from spinal metastases who were treated with surgical decompression, instrumentation, and postoperative radiation delivered as either single-fraction SRS (24 Gy) in 40 patients (21.5%), high-dose hypofractionated SRS (24–30 Gy in 3 fractions) in 37 patients (19.9%), or low-dose hypofractionated SRS (18–36 Gy in 5 or 6 fractions) in 109 patients (58.6%). The relationships between postoperative adjuvant SRS dosing and fractionation, patient characteristics, tumor histology–specific radiosensitivity, grade of ESCC, extent of surgical decompression, response to preoperative radiotherapy, and local tumor control were evaluated by competing risks analysis. Results: The total cumulative incidence of local progression was 16.4% 1 year after SRS. Multivariate Gray competing risks analysis revealed a significant improvement in local control with high-dose hypofractionated SRS (4.1% cumulative incidence of local progression at 1 year, HR 0.12, p = 0.04) as compared with low-dose hypofractionated SRS (22.6% local progression at 1 year, HR 1). Although univariate analysis demonstrated a trend toward greater risk of local progression for patients in whom preoperative conventional external beam radiation therapy failed (22.2% local progression at 1 year, HR 1.96, p = 0.07) compared with patients who did not receive any preoperative radiotherapy (11.2% local progression at 1 year, HR 1), this association was not confirmed with multivariate analysis. No other variable significantly correlated with progression-free survival, including radiation sensitivity of tumor histology, grade of ESCC, extent of surgical decompression, or patient sex. Conclusions: Postoperative adjuvant SRS following epidural spinal cord decompression and instrumentation is a safe and effective strategy for establishing durable local tumor control regardless of tumor histology–specific radiosensitivity. Patients who received high-dose hypofractionated SRS demonstrated 1-year local progression rates of less than 5% (95% CI 0%–12.2%), which were superior to the results of low-dose hypofractionated SRS. The local progression rate after single-fraction SRS was less than 10% (95% CI 0%–19.0%).

1 October 2019 in Cancer Cell
Verified
Journal Article
Closed access
RGRomain Guièze
Romain Guièze
VLVivian M. Liu
Vivian M. Liu
DRDaniel Rosebrock
Daniel Rosebrock
AJAlexis A. Jourdain
Alexis A. Jourdain
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
CWCatherine J. Wu
Catherine J. Wu

4 December 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SGSatyen H. Gohil
Satyen H. Gohil
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
DBDavid A. Braun
David A. Braun
DKDerin B. Keskin
Derin B. Keskin
KLKenneth J. Livak
Kenneth J. Livak